Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors
Andricovich J, Perkail S, Kai Y, Casasanta N, Peng W, Tzatsos A. Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors. Cancer Cell 2018, 33: 512-526.e8. PMID: 29533787, PMCID: PMC5854186, DOI: 10.1016/j.ccell.2018.02.003.Peer-Reviewed Original ResearchConceptsPancreatic cancerCOMPASS-like complexesBET inhibitorsMetastatic pancreatic cancerSensitivity to BET inhibitorsSubtypes of tumorsSpectrum of malignanciesPatient-tailored therapySuper-enhancersActivation of super-enhancersSquamous-likeTumor suppressor functionSquamous differentiationRestrained tumor growthTailored therapyTumor growthTherapeutic nicheKDM6A lossSuppressor functionAberrant activationKDM6ACancerCharacterized mechanismsInhibitorsConcomitant lossThe Perils of Single‐Site Genetic Testing for Hereditary Cancer Syndromes in the Era of Next‐Generation Sequencing
Casasanta N, Stark E, McHenry A, Biagi T, Kaltman R. The Perils of Single‐Site Genetic Testing for Hereditary Cancer Syndromes in the Era of Next‐Generation Sequencing. The Oncologist 2018, 23: 393-396. PMID: 29445031, PMCID: PMC5896713, DOI: 10.1634/theoncologist.2017-0372.Peer-Reviewed Original ResearchConceptsHereditary cancer syndromesCancer syndromesGenetic testingExpanded panel testingOvarian cancer syndromeNational Comprehensive Cancer Network criteriaFemale breast cancerOptimal management of cancer patientsPanel testingClinical genetic testingHereditary genetic syndromesManagement of cancer patientsHereditary breastGenetic riskFamily historyGenetic counselingCell cycle checkpoint arrestCounseling patientsDouble-strand DNA break repairEra of next-generation sequencingBreast cancerNetwork criteriaClinical managementClinical significanceFamily members